IOM Report Offers New Look At U.S. Vaccine Priorities

April 08, 1999

A new study from the Institute of Medicine (IOM) presents important information to help the research community set domestic vaccine priorities for the future. "Vaccines for the 21st Century: A Tool for Decisionmaking," commissioned by the National Institute of Allergy and Infectious Diseases (NIAID), employs a new quantitative model to compare the cost and health benefits of developing more than two dozen different candidate vaccines, including, for the first time, therapeutic vaccines against chronic diseases.

Based on this analysis, the report divides 26 candidate vaccines into four groups, from most to least favorable for development (see page 4). But the IOM report stresses that this ranking is not a recommendation about which candidate vaccines should be developed. Rather, it provides a framework to consider along with other key factors such as technical feasibility and public health urgency when making decisions about vaccine research and development.

"We expect that the NIH and other policy makers in government, academia and industry will find this report and the model it proposes to be extremely valuable tools for guiding vaccine research priority-setting," comments Anthony S. Fauci, M.D., director of NIAID. Anyone with a computer and spreadsheet software will be able to access the model from the IOM free-of-charge and adapt it to other conditions or candidate vaccines.

NIAID - the major supporter of vaccine research nationwide - requested the report in 1995 as a follow-up to two IOM reports issued a decade earlier. A 1985 report focused on priorities for vaccine development in the United States, and a second report, published in 1986, focused on vaccine development in developing countries.

Like the 1985 project, the new report considers only health conditions of public health importance in the United States, except HIV/AIDS, which already is a national priority. However, the new report differs in two significant ways from the 1985 project. First, it includes vaccines not only for infectious diseases, but also therapeutic and preventive vaccines for chronic conditions such as cancer and autoimmune diseases. Second, it evaluates both short-term (10 years) and long-term (20 years) priorities.

As requested, the committee limited their analysis to no more than 30 vaccines that would be feasible to license within 20 years. The quantitative model they created uses health indexes and other analytical methods developed by researchers within the past decade. Vaccine candidates are evaluated according to two primary criteria: anticipated health benefits and expected net savings of health care resources. As new data emerge, specific elements of the model can be changed or new candidate vaccines can be assessed.

"We are pleased that this model provides U.S. policy makers with a common tool to compare vastly divergent health conditions that might be treated or prevented by vaccines," comments N. Regina Rabinovich, M.D., chief of the clinical and regulatory affairs branch in NIAID's Division of Microbiology and Infectious Diseases. Although vaccines against diseases of primarily global importance were not assessed, the report notes that these diseases must be considered in setting research priorities.

The seven vaccines in the top tier include a cytomegalovirus vaccine given to adolescents; a universal influenza vaccine; a Group B streptococcus vaccine for high-risk adults and pregnant women; and a Streptococcus pneumoniae for infants and seniors. In addition, this most favorable group includes therapeutic vaccines for three chronic diseases: rheumatoid arthritis, multiple sclerosis and insulin-dependent diabetes mellitus. Dr. Rabinovich says it is not surprising that these three vaccines fared well in the model. The diseases they target affect large numbers of people; a therapeutic vaccine has a well-defined target population (those ill with the disease); and in this economic model, health benefits accrue more quickly with a therapeutic vaccine than a preventive one. That some therapeutic vaccines appear cost-effective bodes well for vaccine strategies targeted to certain non-infectious, chronic conditions, she says.

The report notes that considerable progress has been made since the 1985 IOM study. Six of 14 vaccines listed in that study as domestic priorities for development are now licensed. These include an acellular pertussis (whooping cough) vaccine and vaccines against hepatitis A and B, Haemophilus influenzae type b (Hib), formerly a major cause of childhood meningitis, varicella zoster (chickenpox), and rotavirus, a leading cause of serious infant diarrhea.

Despite these advances, the report cites legal and other barriers to progress that remain. For example, the Vaccine Injury Compensation Program covers adverse events caused only by vaccines mandated for children. The IOM report lists a striking number of vaccines for use in adolescent or adult populations, vaccines that currently would fall outside this program. Manufacturer liability also is a potential disincentive to developing vaccines for pregnant women to prevent infections such as Group B streptococcus in newborns and young infants.

In addition, to garner public support for the growing number of vaccines, researchers must develop more combination vaccines, rational vaccine schedules and friendly alternatives to injectable vaccines, for example, oral drops and nasal sprays. Finally, the report notes, successfully introducing vaccines into adolescent populations will require acknowledging that that this age group may be sexually active and at risk for certain infectious diseases.

Vaccines are one of the few health care measures that save money, and the cost-effectiveness of all the vaccines in the top three groups compares favorably with that of currently licensed vaccines. However, for the so-called "orphan diseases" in the lowest tier, the report says this expectation needs to shift. In some cases, the health benefits of a vaccine might be worth a higher cost. The report also emphasizes that stable, sufficient funding of basic research by the federal government is crucial to developing vaccines

Robert S. Lawrence, M.D., associate dean for professional education and programs and professor of healthy policy and management at The Johns Hopkins School of Hygiene and Public Health in Baltimore, chaired the 14-member IOM committee. NIAID drafted the project proposal with input from other institutes at the National Institutes of Health (NIH), which funded the project.

(alphabetically ordered within categories)

Most FavorableMore FavorableFavorableLess Favorable
To obtain a printed copy of the full report, call the IOM at 1-800-624-6242. The executive summary of the report is available on the Web at

NIAID is a component of the NIH. NIAID conducts and supports research to prevent, diagnose and treat illnesses such as HIV disease and other sexually transmitted diseases, tuberculosis, malaria, asthma and allergies. NIH is an agency of the U.S. Department of Health and Human Services.

Press releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at

NIH/National Institute of Allergy and Infectious Diseases

Related Public Health Articles from Brightsurf:

COVID-19 and the decolonization of Indigenous public health
Indigenous self-determination, leadership and knowledge have helped protect Indigenous communities in Canada during the coronavirus disease 2019 (COVID-19) pandemic, and these principles should be incorporated into public health in future, argue the authors of a commentary in CMAJ (Canadian Medical Association Journal)

Public health consequences of policing homelessness
In a new study examining homelessness, researchers find that policy such a lifestyle has massive public health implications, making sleeping on the street even MORE unhealthy.

Electronic health information exchange improves public health disease reporting
Disease tracking is an important area of focus for health departments in the midst of the COVID-19 pandemic.

Pandemic likely to cause long-term health problems, Yale School of Public Health finds
The coronavirus pandemic's life-altering effects are likely to result in lasting physical and mental health consequences for many people--particularly those from vulnerable populations--a new study led by the Yale School of Public Health finds.

The Lancet Public Health: US modelling study estimates impact of school closures for COVID-19 on US health-care workforce and associated mortality
US policymakers considering physical distancing measures to slow the spread of COVID-19 face a difficult trade-off between closing schools to reduce transmission and new cases, and potential health-care worker absenteeism due to additional childcare needs that could ultimately increase mortality from COVID-19, according to new modelling research published in The Lancet Public Health journal.

The Lancet Public Health: Access to identification documents reflecting gender identity may improve trans mental health
Results from a survey of over 20,000 American trans adults suggest that having access to identification documents which reflect their identified gender helps to improve their mental health and may reduce suicidal thoughts, according to a study published in The Lancet Public Health journal.

The Lancet Public Health: Study estimates mental health impact of welfare reform, Universal Credit, in Great Britain
The 2013 Universal Credit welfare reform appears to have led to an increase in the prevalence of psychological distress among unemployed recipients, according to a nationally representative study following more than 52,000 working-age individuals from England, Wales, and Scotland over nine years between 2009-2018, published as part of an issue of The Lancet Public Health journal on income and health.

BU researchers: Pornography is not a 'public health crisis'
Researchers from the Boston University School of Public Health (BUSPH) have written an editorial in the American Journal of Public Health special February issue arguing against the claim that pornography is a public health crisis, and explaining why such a claim actually endangers the health of the public.

The Lancet Public Health: Ageism linked to poorer health in older people in England
Ageism may be linked with poorer health in older people in England, according to an observational study of over 7,500 people aged over 50 published in The Lancet Public Health journal.

Study: Public transportation use linked to better public health
Promoting robust public transportation systems may come with a bonus for public health -- lower obesity rates.

Read More: Public Health News and Public Health Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to